Nordion Inc reported a significant increase in revenue derived from the sale of medical isotopes with the return of the NRU reactor to service. Sales of medical isotopes for Q4/10 were $94.4 million, up 49% from Q4/09 sales of $58.0 million. Revenues for the whole year were down slightly, however, from $240.4 million in 2009 to $231.3 million in 2010. A reduction in medical isotopes resulting from a scheduled one-month shut-down of the NRU in April will be partially offset by the start of medical isotopes from Nordion's Russian supplier, Isotope....